Acromegaly is a chronic disorder that is characterized by increased growth hormone secretion and raised insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma. The disease is a very rare condition, and each year, about three new cases of Acromegaly occur for every million people. Acromegaly occurs in the majority of the patients from GH-producing pituitary adenomas. Based on the type of adenomas, the Acromegaly is classified into two groups, i.e., Macroadenomas and Microadenomas. The main aim of treatment is to decrease GH and IGF-1 levels to normal. Treatment may be surgery, pituitary irradiation (radiation therapy on the pituitary gland), medication, or a combination of these options.
Acromegaly Epidemiological Segmentation
- The Epidemiological Segmentation of Acromegaly in 7MM from 2017 to 2030 is segmented as:-
- Total prevalent cases of Acromegaly
- Diagnosed cases of Acromegaly
- Origin-specific diagnosed prevalent cases of Acromegaly
- Diagnosed cases of Acromegaly based on types of adenomas
- The total prevalent cases of Acromegaly were 64,508 in 2017.
- The diagnosed patient pool cases in 2017 were 49,814.
- The prevalent population of Acromegaly in the United States in 2017 was 28,671.
The market size of Acromegaly in 7MM in 2017 was USD 956.96 Million.
Acromegaly Market Drivers
- Robust pipeline
- Increase in prevalence
- More efficacious mono and combination therapies.
Acromegaly Market Barriers
- Economic burden
- Low disease awareness
- Delay in diagnosis
- No standard cure available
Acromegaly Emerging Drugs
Acromegaly Emerging Drugs are IONIS-GHR-LRx, Mycapssa (Octreotide Capsules), ATL1103, CAM2029, GT-02037 (G-SRIF), Veldoreotide (COR-005, DG3173), Paltusotine (CRN00808), MTD201, Lanreotide PRF and others.
Acromegaly Key Players
Acromegaly key players are Ionis Pharmaceuticals, Chiasma Pharma, Antisense Therapeutics, Camurus, GlyTech, Strongbridge Biopharma, Crinetics Pharmaceuticals, Midatech, Ipsen and others.